- |||||||||| [VIRTUAL] TRENDS IN HEPATOCELLULAR CARCINOMA AND ANTIVIRAL HEPATITIS TREATMENT IN OLDER AMERICANS () - Oct 21, 2021 - Abstract #AASLD2021AASLD_913;
Despite a marked increase in the effectiveness and frequency of HCV treatment in 2014 and 2015, HCV-attributable HCC continued to rise through 2015. Future studies should examine the incidence of HCV-attributable HCC among older Americans in subsequent years to assess the effect of the introduction of DAA therapies for HCV in this population .
- |||||||||| Pegasys (pegylated interferon α -2a) / Roche
Clinical, Journal: Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children with Immune-tolerant Chronic Hepatitis B. (Pubmed Central) - Oct 16, 2021
Future studies should examine the incidence of HCV-attributable HCC among older Americans in subsequent years to assess the effect of the introduction of DAA therapies for HCV in this population . The antiviral regimen evaluated in this trial had an acceptable tolerability profile, but was ineffective in children and adolescents with immune-tolerant CHB.
- |||||||||| lamivudine HBV / Generic mfg.
Review, Journal, Adverse events: Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. (Pubmed Central) - Oct 15, 2021
A total of 120 articles were selected for analysis, comprising 6419 patients treated with lamivudine (LAM), 5947 with entecavir (ETV), 3566 with tenofovir disoproxil fumarate (TDF), 3096 with telbivudine (LdT), 1178 with adefovir dipivoxil (ADV) and 876 with tenofovir alafenamide (TAF)...PROSPERO Registration No. CRD42018086471.
- |||||||||| lamivudine HBV / Generic mfg.
Clinical, Review, Journal: Treatment of hepatitis B virus infection in children and adolescents. (Pubmed Central) - Oct 12, 2021
Both United States Food and Drug Administration (US-FDA) and European Medicines Agency (EMA) have approved interferon alfa-2b for children aged 1 year and older, pegylated interferon alfa-2a and lamivudine for children aged 3 years and older, entecavir for use in children aged 2 years and older, and adefovir for use in those 12 years of age and older...Finally, EMA has approved the use of tenofovir alafenamide for treatment of children aged 12 years and older or for children weighing more than 35 kg independent of age. This narrative review will provide the framework for summarizing indications to antiviral therapy in the management of chronic HBV infection in children and adolescents.
- |||||||||| tenofovir disoproxil fumarate / Generic mfg., entecavir / Generic mfg., lamivudine HBV / Generic mfg.
[VIRTUAL] ENTECAVIR VS. TENOFOVIR ON THE RISK OF HCC IN A U.S. COHORT WITH CHRONIC HEPATITIS B VIRUS () - Oct 7, 2021 - Abstract #AASLD2021AASLD_245;
We adjusted for confounders including age, gender, race, diabetes, obesity, alcohol use, HCV, chronic kidney disease, baseline HBV DNA, HBe antigen status, baseline cirrhosis, and prior IFN or lamivudine treatment... In this national cohort of US veterans with chronic HBV treated with TDF or ETV, there was trend toward lower HCC risk developing in patients treated TDF .
- |||||||||| lamivudine HBV / Generic mfg.
Clinical, Journal: Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations. (Pubmed Central) - Oct 6, 2021
In conclusion, HBV RAMs/VEMs have been found globally and across genotypes, with the highest prevalence observed in genotype C. Screening for genotype and for resistance-associated mutations may help to improve stratified patient treatment. As NAs and HBV vaccines are increasingly being deployed for HBV prevention and treatment, monitoring for resistance and advocating for better treatment regimens for HBV remains essential.
- |||||||||| lamivudine HBV / Generic mfg.
Preclinical, Journal: Anti-hepatitis B virus activity and hepatoprotective effect of des(rhamnosyl) verbascoside from Lindernia ruellioides in vitro. (Pubmed Central) - Sep 30, 2021
Although clinically approved hepatitis B virus (HBV) polymerase inhibitors (lamivudine-3TC, entecavir, etc.) serve as effective therapeutics, the virus can easily generate resistance to them...Most of the cells returned to normal morphology, showing polygonal or fusiform structures. Thus, it may be stated that des(rhamnosyl) verbascoside exhibits anti-HBV activity and hepatoprotective effects in vitro and may exert an anti-HBV effect via antigen inhibition, HBV DNA secretion, and HBx protein expression.
- |||||||||| lamivudine HBV / Generic mfg.
Liver fibrosis in a cohort of young HIV-HBV patients after 17 years of antiretroviral treatment (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_680;
We report the development of a screening system that is useful for identifying non-nucleos(t)ide RT inhibitors. Lamivudine (3tc) was used in 50 (48.1%) of cases and tenofovir disoproxil/tenofovir alafenamide in 47 (45.2%) of cases... In HIV/HBV patients no correlation was found between liver fibrosis and antiretroviral drug classes or hepatic and metabolic markers despite the prolonged treatment, suggesting that other factors could contribute to the development of liver injury in these patients.
- |||||||||| lamivudine HBV / Generic mfg.
Liver fibrosis in a cohort of young HIV-HBV patients after 17 years of antiretroviral treatment (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_213;
Lamivudine (3tc) was used in 50 (48.1%) of cases and tenofovir disoproxil/tenofovir alafenamide in 47 (45.2%) of cases... In HIV/HBV patients no correlation was found between liver fibrosis and antiretroviral drug classes or hepatic and metabolic markers despite the prolonged treatment, suggesting that other factors could contribute to the development of liver injury in these patients. Lamivudine (3tc) was used in 50 (48.1%) of cases and tenofovir disoproxil/tenofovir alafenamide in 47 (45.2%) of cases... In HIV/HBV patients no correlation was found between liver fibrosis and antiretroviral drug classes or hepatic and metabolic markers despite the prolonged treatment, suggesting that other factors could contribute to the development of liver injury in these patients.
- |||||||||| Isentress (raltegravir) / Merck (MSD)
PK/PD data, Journal: Characterization of Seasonal Pharmacokinetic Variability in Woodchucks. (Pubmed Central) - Sep 15, 2021
These compounds were selected to study changes in oxidative metabolism [antipyrine (AP)], glucuronidation [raltegravir (RTG)], renal clearance [lamivudine (3TC)], and hepatic function [indocyanine green (ICG)]...Investigation of seasonal PK changes is perhaps of greater interest to pharmaceutical industry scientists using the woodchuck model to optimize the scheduling of woodchuck studies to avoid seasonally-driven variation in drug PK and/or toxicity. This information is also valuable to drug metabolism and veterinary scientists in understanding woodchuck's seasonal metabolism and behavior under the pseudo-hibernation condition.
- |||||||||| tenofovir disoproxil fumarate / Generic mfg., entecavir / Generic mfg., lamivudine HBV / Generic mfg.
Review, Journal, Combination therapy: Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. (Pubmed Central) - Sep 15, 2021
However, responses to the combination of non-pegylated IFNα with lamivudine or adefovir were not assessed based on HBsAg quantification but were defined by normal alanine aminotransferase levels, testing negative for hepatitis B e-antigen, and low HBV DNA load over a short term...Some studies have shown promising results, but there is no robust evidence that combination therapy is superior to monotherapy. Large studies are needed to assess the safety and efficacy of combination therapies to increase the rates of HBsAg seroclearance over the long term.
- |||||||||| lamivudine HBV / Generic mfg.
Clinical, Journal: Serum Vitamin D Levels in Chronic Hepatitis B Patients Before and During Treatment. (Pubmed Central) - Sep 11, 2021
The present study highlights the impact of antiviral therapy on vitamin D deficiency in CHB patients, where effective therapy improves vitamin D levels. Meanwhile, it is recommended to study the impact of vitamin D replacement and correction on the disease progression or regression.
- |||||||||| lamivudine HBV / Generic mfg.
Retrospective data, Journal: Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China. (Pubmed Central) - Sep 4, 2021
In a multivariate analysis, age group [odds ratio (OR) = 2.387], diabetes mellitus (OR = 1.486), hypertension (OR = 2.557), hepatic cirrhosis (OR = 1.295), and a history of exposure to adefovir dipivoxil (OR = 1.644) were significantly associated with CKD (P < 0.05). Among patients with CKD, 17.66% (107/606) had a history of lamivudine exposure, and 34.65% (210/606) had a history of nucleotide analogue exposure The management of Chinese patients with CHB should take into consideration age, previous medication history, and renal impairment.
- |||||||||| lamivudine HBV / Generic mfg.
Clinical, Journal: De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected pediatric patients with advanced fibrosis. (Pubmed Central) - Sep 2, 2021
We prospectively enrolled treatment-naı̈ve paediatric patients between 1 year and 12 years of age who had e antigen-negative chronic hepatitis B and histologically proven advanced fibrosis. All patients received de novo combination therapy with lamivudine (LAM) and interferon-α (IFN) for 12 months and then were clinically followed up...Combination antiviral therapy is beneficial to e antigen-negative chronic hepatitis B virus-infected pediatric patients with advanced fibrosis. Further studies with larger cohorts are required.
- |||||||||| Tyzeka (telbivudine) / Novartis
Journal: Developmental Consequences of Prenatal Telbivudine Exposure during the Third Trimester. (Pubmed Central) - Aug 20, 2021
P=N/A
Conclusions The developmental consequences of prenatal telbivudine exposure were comparable to those without the exposure in one year observation. We now know that Telbivudine therapy is safe for hepatitis B mothers during pregnancy; ClincialTrials.gov number, NCT02301650.
- |||||||||| lamivudine HBV / Generic mfg.
[VIRTUAL] Prevention of Maternal to Child Transmission of HBV Infection () - Aug 19, 2021 - Abstract #APDW2021APDW_175;
More recently, tenofovir disoproxil fumarate (TDF) which has replaced the lamivudine and telbivudine as first line antiviral drug for Hepatitis B, has also been shown to be effective and safe in preventing MTCT...The use of antiviral prophylaxis together with immunoprophylaxis with Hepatitis B vaccine and HBIG is recommended by all the major liver societies and by the WHO. This would contribute to the global efforts towards HBV elimination.
- |||||||||| lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Clinical, Journal: Blood exchange transfusion in viral hepatitis in a small infant: a case report. (Pubmed Central) - Aug 7, 2021
After each blood exchange transfusion, the biochemical values (bilirubin, liver enzymes, and coagulation profile) gradually improved and he was discharged after 1 month of treatment. Blood exchange transfusion is an effective procedure for managing acute liver failure, where plasma exchange is not possible while waiting for the recovery of liver functions or liver transplantation.
- |||||||||| lamivudine HBV / Generic mfg.
Journal: Donor Derived Hepatitis B Virus Infection: Analysis of the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee. (Pubmed Central) - Aug 5, 2021
Of the 10 liver recipients and 1 liver-kidney recipient who received organs from these donors: six were not given antiviral prophylaxis, two developed infection after antiviral prophylaxis was discontinued, two developed HBV while on lamivudine prophylaxis, one was on antiviral prophylaxis and did not develop HBV viremia or antigenemia...Unexpected donor-derived transmission of HBV was a rare event in reports to DTAC, but was often detected in the recipient late post-transplant. Six of 11 recipients (54.5%) of a liver from a HBcAb positive donor did not receive prophylaxis; all of these were potentially preventable with the use of anti-viral prophylaxis.
- |||||||||| lamivudine HBV / Generic mfg.
Journal: Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents. (Pubmed Central) - Jul 28, 2021
Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC values of 0.19 and 0.18 μM, respectively...Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π-π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.
- |||||||||| lamivudine HBV / Generic mfg.
Clinical, Journal: Prevention and treatment of new hepatitis B after living donor liver transplantation in children. (Pubmed Central) - Jul 28, 2021
After their operations, the children were given lamivudine for anti-hepatitis B virus (HBV) treatment, a hepatitis B vaccine or intermittent supplements of hepatitis B immunoglobulins to prevent recurrence of the infection, and entecavir for anti-hepatitis B treatment...The long-term prophylactic therapy of nucleoside analogues combined with hepatitis B immunoglobulins should be used for a long time after liver transplantation with a liver positive for HBcAg. Discontinuation of nucleoside analogues is associated with a higher risk of the new onset of hepatitis B. Entecavir has a significant effect on the treatment of postoperative new hepatitis B in children.
- |||||||||| lamivudine HBV / Generic mfg.
Preclinical, Journal: A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. (Pubmed Central) - Jul 17, 2021
To this end, we modified lamivudine (3TC), a nucleoside analog inhibitor of both viruses, into a lipophilic monophosphorylated prodrug (M23TC)...A single intramuscular dose of 75mg/kg 3TC equivalents of nanoformulated NM23TC provided sustained drug levels and suppressed HBV replication in humanized mice for 4weeks. The results support further development of this long-acting 3TC nanoformulation for HBV treatment and prevention.
- |||||||||| lamivudine HBV / Generic mfg.
Journal: Synthesis and Bioactivity of N-(4-Chlorophenyl)-4-Methoxy-3-(Methylamino) Benzamide as a Potential Anti-HBV Agent. (Pubmed Central) - Jul 9, 2021
Our results show that IMB-0523 has higher anti-HBV activity in both wild-type HBV (IC: 1.99 µM) and drug-resistant HBV (IC: 3.30 µM) than lamivudine (3TC, IC: 7.37 µM in wild-type HBV, IC: >440 µM in drug-resistant HBV)...Further, IMB-0523 showed potent anti-HBV activity in DHBV-infected ducks. Thus, IMB-0523 may be a potential anti-HBV agent with different mechanisms than current anti-HBV treatment options.
- |||||||||| undisclosed HBV therapeutic / Kainos Medicine, Institut Pasteur Korea
Journal: A new high-content screening assay of the entire hepatitis B virus life cycle identifies novel antivirals. (Pubmed Central) - Jul 6, 2021
Patient-derived HBV genotype C was efficiently inhibited by fludarabine (EC 0.08 μM) and dexmedetomidine (EC 8.7 μM)...We used this system to screen drug libraries and identified novel anti-HBV inhibitors that potently inhibit HBV in various phases of its life cycle. This assay will be an important new tool to study the HBV life cycle and accelerate the development of novel therapeutic strategies.
- |||||||||| zidovudine / Generic mfg., lamivudine HBV / Generic mfg.
Journal: Structural dynamics and susceptibility of anti-HIV drugs against HBV reverse transcriptase. (Pubmed Central) - Jul 4, 2021
In the present study, we aimed to investigate the structural dynamics and susceptibility of the known anti-HIV drugs (stavudine [d4T], didanosine [DDI], and zidovudine [ZDV]) against HBV-RT enzyme in comparison to the anti-HBV drug lamivudine (3TC) and deoxythymidine triphosphate (dTTP) substrate using several computational approaches...The predicted binding free energy results based on QM/MM-GBSA and MM/GB(PB)SA methods suggested that the susceptibility towards HBV-RT of d4T and ZDV is higher than that of 3TC and dTTP. Altogether, this work sheds light on the potentiality of d4T and ZDV as a promising drug for HBV-infected patients harboring 3TC resistance.Communicated by Ramaswamy H. Sarma.
- |||||||||| Vemlidy (tenofovir alafenamide) / Gilead
Journal: Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide. (Pubmed Central) - Jun 30, 2021
ETV may be less effective in patients with lamivudine-resistant strains, and TDF is associated with impaired renal function and reductions in bone mineral density...The main limitation to prescribing TAF is its price. The European Association for the Study of the Liver has suggested selecting TAF or ETV instead of TDF in patients >65 years old and in those with a risk of osteoporosis or renal abnormalities, and to prescribe TAF rather than ETV in patients previously exposed to NAs.
|
